Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Residence Characteristics | 14 | 2025 | 292 | 3.370 |
Why?
|
| Socioeconomic Factors | 12 | 2025 | 897 | 1.900 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2024 | 998 | 1.680 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1387 | 1.520 |
Why?
|
| Texas | 23 | 2025 | 3615 | 1.260 |
Why?
|
| Cyclonic Storms | 4 | 2023 | 78 | 1.160 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2024 | 256 | 1.010 |
Why?
|
| Transportation | 2 | 2019 | 27 | 1.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 849 | 0.900 |
Why?
|
| Schools | 6 | 2025 | 240 | 0.840 |
Why?
|
| Walking | 4 | 2019 | 234 | 0.800 |
Why?
|
| Environment Design | 4 | 2019 | 16 | 0.790 |
Why?
|
| Pediatric Obesity | 6 | 2025 | 416 | 0.780 |
Why?
|
| Floods | 3 | 2022 | 22 | 0.760 |
Why?
|
| Registries | 7 | 2024 | 1599 | 0.760 |
Why?
|
| Arsenic | 1 | 2023 | 48 | 0.760 |
Why?
|
| Health Status Disparities | 4 | 2024 | 278 | 0.730 |
Why?
|
| Social Class | 3 | 2025 | 211 | 0.670 |
Why?
|
| Disasters | 1 | 2021 | 101 | 0.620 |
Why?
|
| Public Facilities | 1 | 2019 | 2 | 0.600 |
Why?
|
| Bicycling | 1 | 2019 | 35 | 0.590 |
Why?
|
| Incidence | 8 | 2024 | 3347 | 0.550 |
Why?
|
| Geographic Information Systems | 2 | 2015 | 40 | 0.550 |
Why?
|
| Hypersensitivity | 1 | 2021 | 231 | 0.550 |
Why?
|
| Overweight | 1 | 2020 | 377 | 0.540 |
Why?
|
| Stress, Psychological | 2 | 2021 | 562 | 0.530 |
Why?
|
| Pandemics | 5 | 2023 | 1161 | 0.510 |
Why?
|
| Mexican Americans | 2 | 2015 | 166 | 0.490 |
Why?
|
| Exercise | 2 | 2019 | 866 | 0.460 |
Why?
|
| Communicable Disease Control | 5 | 2023 | 141 | 0.430 |
Why?
|
| Safety | 2 | 2016 | 215 | 0.430 |
Why?
|
| Humans | 53 | 2025 | 131604 | 0.420 |
Why?
|
| Male | 43 | 2025 | 65228 | 0.420 |
Why?
|
| Female | 38 | 2025 | 71145 | 0.410 |
Why?
|
| Spatial Analysis | 2 | 2024 | 28 | 0.390 |
Why?
|
| Health Behavior | 4 | 2020 | 390 | 0.380 |
Why?
|
| Adult | 19 | 2025 | 31702 | 0.370 |
Why?
|
| Fenfluramine | 3 | 1997 | 12 | 0.350 |
Why?
|
| Motor Activity | 2 | 2014 | 507 | 0.340 |
Why?
|
| Parents | 2 | 2016 | 1109 | 0.320 |
Why?
|
| Middle Aged | 14 | 2025 | 28883 | 0.310 |
Why?
|
| Environmental Exposure | 2 | 2024 | 291 | 0.310 |
Why?
|
| Analgesics | 4 | 1994 | 122 | 0.290 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3834 | 0.280 |
Why?
|
| Adolescent | 16 | 2025 | 20931 | 0.270 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 578 | 0.270 |
Why?
|
| Surveys and Questionnaires | 10 | 2024 | 4039 | 0.260 |
Why?
|
| Aged | 10 | 2025 | 21255 | 0.260 |
Why?
|
| United States | 14 | 2025 | 11800 | 0.260 |
Why?
|
| Child | 16 | 2025 | 26250 | 0.250 |
Why?
|
| Young Adult | 9 | 2025 | 10094 | 0.250 |
Why?
|
| Child, Preschool | 8 | 2024 | 15054 | 0.230 |
Why?
|
| Research Design | 5 | 2020 | 722 | 0.230 |
Why?
|
| Social Environment | 2 | 2016 | 122 | 0.230 |
Why?
|
| Sex Characteristics | 3 | 2023 | 338 | 0.220 |
Why?
|
| Culex | 1 | 2024 | 33 | 0.220 |
Why?
|
| Mosquito Vectors | 1 | 2024 | 36 | 0.220 |
Why?
|
| Safety-net Providers | 1 | 2025 | 88 | 0.220 |
Why?
|
| Geography, Medical | 1 | 2023 | 17 | 0.210 |
Why?
|
| Serotonin | 2 | 1994 | 212 | 0.200 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 111 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 162 | 0.190 |
Why?
|
| Hypothalamus | 2 | 1994 | 205 | 0.190 |
Why?
|
| Pain | 4 | 2022 | 439 | 0.190 |
Why?
|
| Wounds, Gunshot | 1 | 2024 | 145 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2025 | 312 | 0.190 |
Why?
|
| Endocrine Disruptors | 1 | 2022 | 55 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 226 | 0.180 |
Why?
|
| Peritoneal Dialysis | 1 | 2023 | 131 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 375 | 0.170 |
Why?
|
| Arginine Vasopressin | 2 | 1992 | 25 | 0.170 |
Why?
|
| Sociological Factors | 1 | 2021 | 9 | 0.170 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2022 | 79 | 0.170 |
Why?
|
| Workplace Violence | 1 | 2020 | 3 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 329 | 0.170 |
Why?
|
| Health Services Accessibility | 3 | 2025 | 696 | 0.170 |
Why?
|
| Social Isolation | 1 | 2020 | 43 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2023 | 441 | 0.160 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 78 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 502 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 389 | 0.160 |
Why?
|
| House Calls | 1 | 2020 | 36 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 190 | 0.160 |
Why?
|
| Receptors, Serotonin | 2 | 1997 | 37 | 0.160 |
Why?
|
| Public Opinion | 1 | 2020 | 63 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 179 | 0.150 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1894 | 0.150 |
Why?
|
| Cities | 1 | 2019 | 53 | 0.150 |
Why?
|
| Stress, Physiological | 2 | 1991 | 262 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 207 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 132 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 265 | 0.140 |
Why?
|
| Outpatients | 1 | 2020 | 266 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2021 | 392 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17666 | 0.140 |
Why?
|
| Survivors | 1 | 2020 | 354 | 0.140 |
Why?
|
| Health Status | 1 | 2020 | 387 | 0.140 |
Why?
|
| Educational Status | 2 | 2021 | 281 | 0.140 |
Why?
|
| Social Media | 1 | 2020 | 119 | 0.140 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 130 | 0.140 |
Why?
|
| Community Networks | 1 | 2017 | 30 | 0.130 |
Why?
|
| Interleukin-1 | 2 | 1995 | 131 | 0.130 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1997 | 3 | 0.130 |
Why?
|
| Thiazepines | 1 | 1997 | 7 | 0.130 |
Why?
|
| Eating | 2 | 1997 | 382 | 0.130 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1997 | 29 | 0.130 |
Why?
|
| Appetite Depressants | 1 | 1997 | 23 | 0.130 |
Why?
|
| Mental Health | 1 | 2020 | 382 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Fluoxetine | 1 | 1997 | 45 | 0.130 |
Why?
|
| Attitude to Health | 2 | 2015 | 251 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 463 | 0.120 |
Why?
|
| Behavior, Animal | 3 | 1997 | 510 | 0.120 |
Why?
|
| Hospitals | 1 | 2019 | 445 | 0.120 |
Why?
|
| Hypertension | 1 | 2025 | 1360 | 0.120 |
Why?
|
| Mice, Inbred Strains | 6 | 1995 | 297 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2023 | 952 | 0.120 |
Why?
|
| Neoplasms | 3 | 2024 | 2969 | 0.110 |
Why?
|
| Prednisolone | 1 | 1995 | 69 | 0.110 |
Why?
|
| Indomethacin | 1 | 1995 | 81 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 639 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 366 | 0.110 |
Why?
|
| Survival Rate | 1 | 2020 | 2151 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.110 |
Why?
|
| Norfenfluramine | 1 | 1994 | 1 | 0.110 |
Why?
|
| Family Relations | 1 | 2015 | 72 | 0.110 |
Why?
|
| Naloxone | 2 | 1991 | 47 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2014 | 89 | 0.110 |
Why?
|
| School Health Services | 1 | 2015 | 103 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 506 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5296 | 0.100 |
Why?
|
| Feeding and Eating Disorders | 1 | 1994 | 74 | 0.100 |
Why?
|
| Physicians | 1 | 2020 | 634 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2015 | 175 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2015 | 220 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 302 | 0.100 |
Why?
|
| Receptors, Vasopressin | 1 | 1992 | 13 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1995 | 303 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 200 | 0.100 |
Why?
|
| Dopamine | 1 | 1994 | 256 | 0.100 |
Why?
|
| Body Temperature Regulation | 1 | 1992 | 51 | 0.090 |
Why?
|
| Codeine | 1 | 1992 | 22 | 0.090 |
Why?
|
| Morphine | 1 | 1992 | 80 | 0.090 |
Why?
|
| Behavioral Medicine | 1 | 2011 | 11 | 0.090 |
Why?
|
| Students | 1 | 2014 | 251 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1992 | 139 | 0.090 |
Why?
|
| Models, Educational | 1 | 2011 | 75 | 0.090 |
Why?
|
| Histamine | 1 | 1991 | 52 | 0.090 |
Why?
|
| Asthma | 1 | 2020 | 927 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1990 | 6 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2017 | 787 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1990 | 40 | 0.080 |
Why?
|
| Prognosis | 1 | 2020 | 4952 | 0.080 |
Why?
|
| Analgesia | 1 | 1990 | 43 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1516 | 0.080 |
Why?
|
| Research Personnel | 1 | 2011 | 139 | 0.080 |
Why?
|
| Nociceptors | 1 | 1990 | 14 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 1994 | 781 | 0.080 |
Why?
|
| Injections, Intraventricular | 4 | 1992 | 53 | 0.070 |
Why?
|
| Animals | 12 | 2024 | 34371 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 1994 | 724 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 1151 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 2694 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2014 | 1695 | 0.070 |
Why?
|
| Inflammation | 1 | 1995 | 1492 | 0.070 |
Why?
|
| Pain Measurement | 3 | 1994 | 354 | 0.060 |
Why?
|
| Brain | 2 | 1997 | 3238 | 0.060 |
Why?
|
| Linear Models | 2 | 2021 | 695 | 0.060 |
Why?
|
| Sex Factors | 2 | 2021 | 1346 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2011 | 556 | 0.060 |
Why?
|
| Population Density | 1 | 2024 | 31 | 0.060 |
Why?
|
| Rats | 3 | 1997 | 3460 | 0.060 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 10 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3094 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2025 | 251 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 10959 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 31 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 2872 | 0.050 |
Why?
|
| Mice | 8 | 1995 | 18486 | 0.050 |
Why?
|
| Environmental Health | 1 | 2023 | 21 | 0.050 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 117 | 0.050 |
Why?
|
| Firearms | 1 | 2024 | 58 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2024 | 139 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 148 | 0.050 |
Why?
|
| Focus Groups | 1 | 2023 | 228 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 2 | 1994 | 66 | 0.050 |
Why?
|
| Silicones | 1 | 2022 | 32 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 127 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2022 | 66 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2021 | 36 | 0.040 |
Why?
|
| Hepatoblastoma | 1 | 2024 | 187 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2022 | 77 | 0.040 |
Why?
|
| Marital Status | 1 | 2021 | 33 | 0.040 |
Why?
|
| Physical Exertion | 2 | 1991 | 67 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1831 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2023 | 205 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 361 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 150 | 0.040 |
Why?
|
| Hot Temperature | 2 | 1991 | 144 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 37 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 81 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1625 | 0.040 |
Why?
|
| Fever | 1 | 2022 | 311 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 220 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 119 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1405 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 1040 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 169 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 418 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 558 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 260 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 236 | 0.040 |
Why?
|
| Infant | 2 | 2024 | 13305 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 117 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 276 | 0.030 |
Why?
|
| Life Style | 1 | 2021 | 444 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 228 | 0.030 |
Why?
|
| Serotonin Agents | 1 | 1997 | 15 | 0.030 |
Why?
|
| Neuropeptide Y | 1 | 1997 | 34 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1997 | 116 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 1997 | 55 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 684 | 0.030 |
Why?
|
| Zymosan | 1 | 1995 | 3 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 1995 | 15 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1995 | 67 | 0.030 |
Why?
|
| Peroxidase | 1 | 1995 | 64 | 0.030 |
Why?
|
| Formaldehyde | 2 | 1992 | 41 | 0.030 |
Why?
|
| Granuloma | 1 | 1995 | 63 | 0.030 |
Why?
|
| Fenclonine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1595 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 902 | 0.030 |
Why?
|
| Microdialysis | 1 | 1994 | 59 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2015 | 98 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1994 | 709 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2015 | 63 | 0.030 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1994 | 9 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1994 | 28 | 0.030 |
Why?
|
| Food Deprivation | 1 | 1994 | 34 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1994 | 129 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 1994 | 159 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 1994 | 154 | 0.030 |
Why?
|
| Abdomen | 1 | 1994 | 133 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 371 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 643 | 0.020 |
Why?
|
| Oxymorphone | 1 | 1992 | 1 | 0.020 |
Why?
|
| Body Weight | 1 | 1997 | 990 | 0.020 |
Why?
|
| Receptors, Histamine | 1 | 1991 | 3 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2014 | 317 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 1991 | 17 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1991 | 40 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1217 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 1992 | 112 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 5123 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 407 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8588 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 141 | 0.020 |
Why?
|
| Parenting | 1 | 2015 | 349 | 0.020 |
Why?
|
| Swimming | 1 | 1990 | 30 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2011 | 197 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1990 | 156 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2564 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 241 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2113 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2025 | 12964 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3615 | 0.020 |
Why?
|
| Reaction Time | 1 | 1990 | 157 | 0.020 |
Why?
|
| Cognition | 1 | 2014 | 843 | 0.020 |
Why?
|
| Arginine | 1 | 1991 | 344 | 0.020 |
Why?
|
| Anxiety | 1 | 2015 | 1003 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 2143 | 0.020 |
Why?
|
| Diet | 1 | 1994 | 1121 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 2037 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6922 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1991 | 57 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1991 | 111 | 0.010 |
Why?
|
| Edema | 1 | 1991 | 139 | 0.000 |
Why?
|
| Nitric Oxide | 1 | 1991 | 466 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1991 | 1344 | 0.000 |
Why?
|